08:00 , Dec 7, 2009 |  BC Week In Review  |  Clinical News

GFT505: Phase II data

In the 28-day, double-blind, international Phase IIa GFT505-2083 trial in 97 pre-diabetics with atherogenic dyslipidemia and abdominal obesity, 80 mg/day oral GFT505 met the co-primary endpoints and multiple secondary endpoints. On the co-primary endpoints, GFT505...
08:00 , Dec 18, 2008 |  BC Innovations  |  Distillery Techniques

This week in techniques

The Distillery: Techniques Approach Summary Licensing status Publication and contact information Markers Assessment of pulmonary arterial hypertension (PAH) risk in sickle cell disease patients using plasma apolipoproteins Apolipoprotein levels in plasma samples could potentially predict...